Sanofi Group - Bathi resik saben saham (EPS TTM) SNY

Sanofi (SNY) management is effectively reallocating resources toward innovative immunology, enhancing R&D transparency. Changes in the rolling net income per share help identify yield anomalies, where the 1.92 mark indicates the current state. Strict patents ensure monopoly pricing power for vaccines, while targeted deals with biotech startups systematically refresh the company's development pipeline.

SNY (Sanofi) riwayat Bathi resik saben saham sajrone patang kuartal pungkasan saka 04.07.2022 nganti 15.11.2026

Rincian analitis perusahaan Sanofi

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Sanofi S.A.|SNY - Bagan rega target

- rincian nilai pasar emiten:

Kapitalisasi pasar Sanofi|SNY - Nilai Bisnis

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Sanofi|SNY - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku sanofi.com|SNY - Total Aset Bisnis

- indikator beban utang lan likuiditas:

- indikator pendapatan resik lan kelipatan nilai:

SNY - Penghasilan resik perusahaan|Proyeksi bathi mangsa ngarep Sanofi|SNY - Kapitalisasi marang bathi resik|Pangali Forward P/E Sanofi Group|SNY - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Sanofi|SNY - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Sanofi|SNY - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan sanofi.com|SNY - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sanofi

- data total pendapatan lan volume dodolan:

SNY - Pendapatan tahunan perusahaan|Prakiraan volume dodolan Sanofi S.A.|SNY - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Sanofi SA

Analisis fundamental perusahaan:sanofi.com (SNY)

Professional capital evaluates Sanofi (SNY) through the lens of capital expenditure efficiency across its network of global laboratories and plants. By analyzing the change in TTM net income per share, the investor identifies the final profit allocated per security, which allows for an objective measurement of business profitability and confirms the asset's fundamental stability regardless of reporting lags.

Pesaing Sanofi (SNY)